Edward Cliff: The development and clinical trial design of T-cell lymphoma drugs pralatrexate and belinostat

Edward Cliff, Haematology Registrar at Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, shared a post on X about a recent paper titled “US Food and Drug Administration’s Directive to Deal With Delayed Confirmatory Trials: Lessons From Pralatrexate and Belinostat for T-Cell Lymphoma” published in Journal of Clinical Oncology.

Authors: Edward R. Scheffer Cliff, David A. Russler-Germain, C. Joseph Ross Daval and Aaron S. Kesselheim.

“In Journal of Clinical Oncology we review the development and clinical trial design of T-cell lymphoma drugs pralatrexate and belinostat, and discuss strategies for FDA Oncology to deal with delayed confirmatory clinical trials.

Read here.”

Source: Edward Cliff/X